OXFORD and TORONTO, May 17th, 2021 - PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory.
News
Cambridge, 19th May 2021
Cambridge, UK, 18 May 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced a target discovery, option and license agreement with Janssen Biotech, Inc.
The latest issue of Sequence looks at key legal and business issues affecting the sector.
Science park investment/ Patents for ground-breaking inventions/ Shaping the EU-UK relationship/ The new life sciences legal framework and much more:
https://update.mills-reeve.com/12/2613/may-2021/life-sciences---sequence...
Giggabox is set to dramatically scale its Virtual & Hybrid Events offerings to clients as we have secured sizeable investment. This funding has been received from First Enterprise – Enterprise Loans through the Midlands Engine Investment Fund (MEIF). These extra resources will be utilised for the purchase of additional remote digital production equipment and for hiring seven new production and technical employees to help meet the growing demand for live online conferences, product launches, and digital events.
001 Limited, an independent commercial energy and utility specialists, have recently joined One Nucleus and are excited to start connecting with fellow members from the Life Science industry.
Since 2001, 001 Limited has been using its expertise and experience of the energy market to help businesses across all industries to source sustainable solutions, secure competitive utility contracts and recover savings through conducting historic audits.
COVID-19 swept the globe during 2020 leading to significant morbidity and mortality, impacting all aspects of life, including health and social care provision. This report, published today, demonstrates how people living with rare conditions were disproportionately affected.
In early 2020 a cross-sector group of concerned advocates came together to take Action for Rare Disease Empowerment (ARDEnt). They aimed to shed light on the unseen impact of the pandemic on people living with rare conditions to protect the precious existing services and build on any opportunities uncovered.
AMSBIO has announced a new range of AAV reference materials of full capsids and empty capsids of 6 different serotypes.
Critical to enable meaningful comparisons between research studies and clinical trials, these well-characterized reference standards are extensively quality analyzed with molecular based assays and transmission electron microscope.
"The acquisition of FGL enables NEB to combine our expertise in enzyme manufacturing and assay development with their expertise in lyophilization, providing a complete solution for our customers," states Jim Ellard, CEO of New England Biolabs. "It also further solidifies our ability to service customers in the molecular diagnostics space."
Building a robust global patent portfolio for its ArestatTM platform